Argenica Therapeutics Says Final Patient Dosed in Phase Two Acute Ischaemic Stroke Drug Candidate Trial; Shares Rise 3%

MT Newswires Live2025-04-11

Argenica Therapeutics (ASX:AGN) said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.

The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.

Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.

Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.

Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2526570829?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-11 11:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2526570829","market":"hk","top_or_hot":-1,"title":"Argenica Therapeutics Says Final Patient Dosed in Phase Two Acute Ischaemic Stroke Drug Candidate Trial; Shares Rise 3%","media":"MT Newswires Live","content":"<html><body><p> Argenica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:AGN) said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.</p><p>The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.</p><p>Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.</p><p>Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.</p><p>Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Argenica Therapeutics Says Final Patient Dosed in Phase Two Acute Ischaemic Stroke Drug Candidate Trial; Shares Rise 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArgenica Therapeutics Says Final Patient Dosed in Phase Two Acute Ischaemic Stroke Drug Candidate Trial; Shares Rise 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-11 11:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Argenica <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:AGN) said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.</p><p>The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.</p><p>Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.</p><p>Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.</p><p>Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2526570829","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2526570829","pubTimestamp":1744340874,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Argenica Therapeutics  said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","AGN.AU":"Argenica Therapeutics Ltd","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"Argenica Therapeutics表示，第二阶段急性缺血性中风候选药物试验的最后一名患者接受了给药；股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGN.AU":0.9,"LENZ":1},"content_text":"Argenica Therapeutics (ASX:AGN) said the the final patient in its phase two clinical trial of ARG-007 in acute ischaemic stroke has been dosed, according to a Friday Australian bourse filing.The phase two trial dosed a total of 92 patients with confirmed large vessel occlusion strokes and who underwent an endovascular thrombectomy procedure to remove the clot.Half of these patients received an intravenous infusion of a saline placebo, and half received an intravenous infusion of ARG-007. The trial will remain blinded until the final patient dosed has their follow-up functional assessment performed at 90 days post-stroke.Top-line data are expected to be released in the third quarter. The trial is seeking to evaluate the safety of the ARG-007 drug candidate and characterize the effect of the candidate on reducing infarct volume in participants with acute ischaemic stroke.Argenica Therapeutics' shares rose almost 3% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2526570829","isCrawlerRequest":true}